VEGF Trap-Eye: Phase III complete enrollment

The partners completed enrollment of more than 1,200 patients in the double-blind, North American Phase III VIEW 1 trial comparing 0.5 mg VEGF Trap-Eye every 4 weeks or 2 mg of VEGF Trap-Eye every 4 o...